Johnson & Johnson (NYSE:JNJ) has decided to resume a limited market rollout of its heart rhythm device Varipulse after an investigation indicated no safety concerns, the MedTech giant announced.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback